A humán leukocytainterferon helye a krónikus hepatitis C kezelésében

Translated title of the contribution: Human leukocyte interferon in the treatment of chronic hepatitis C

L. Telegdy, Horváth Gábor, Tolvaj Gyula, Makara Mihály, Montskó Valéria, Ozsvár Zsófia, Nemes Zsuzsanna, Péterfy Zoltán, Szentgyörgyi László

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

INTRODUCTION - Approximatively 50% of the patients with chronic hepatitis C do not respond properly to pegylated interferon-alpha+ribavirin treatment and according to the therapeutic guidelines their treatment must be interrupted. The authors examined whether their further medication with human leukocyte interferon is justified. PATIENTS AND METHODS - Thirty-eight patients with chronic hepatitis C were treated with human leukocyte interferon who had responded to pegylated interferon-alpha-ribavirin treatment, but dropped out of the treatment scheme based on the therapeutic criteria on week 12 or 24. RESULTS - While only 3 patients responded with persistent virological negativity, mean alanine aminotransferase (ALT) levels decreased during treatment and persistently remained lower than the baseline levels. Except for the three responders, the HCV viral load as determined by polymerase chain reaction did not decrease but even increased on average. Patients tolerated the treatment well. Known side-effects were observed in 6 cases, and treatment had to be interrupted in one case. These are proportionally far less than the respective 20 to 25% and 5 to 15% reported for peginterferon-ribavirin treatment. CONCLUSION - Even though virological recovery is rare, the reduction in inflammatory activity, the expected slowing of progression, and, in particular, the definite improvement of the cryoglobulinaemic purpura and vasculitis warrant switching to human leukocyte interferon treatment in selected cases.

Original languageHungarian
Pages (from-to)783-786
Number of pages4
JournalLege Artis Medicinae
Volume17
Issue number11
Publication statusPublished - Nov 2007

Fingerprint

Chronic Hepatitis C
Interferon-alpha
Ribavirin
Therapeutics
Purpura
Vasculitis
Viral Load
Alanine Transaminase
Guidelines
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Telegdy, L., Gábor, H., Gyula, T., Mihály, M., Valéria, M., Zsófia, O., ... László, S. (2007). A humán leukocytainterferon helye a krónikus hepatitis C kezelésében. Lege Artis Medicinae, 17(11), 783-786.

A humán leukocytainterferon helye a krónikus hepatitis C kezelésében. / Telegdy, L.; Gábor, Horváth; Gyula, Tolvaj; Mihály, Makara; Valéria, Montskó; Zsófia, Ozsvár; Zsuzsanna, Nemes; Zoltán, Péterfy; László, Szentgyörgyi.

In: Lege Artis Medicinae, Vol. 17, No. 11, 11.2007, p. 783-786.

Research output: Contribution to journalArticle

Telegdy, L, Gábor, H, Gyula, T, Mihály, M, Valéria, M, Zsófia, O, Zsuzsanna, N, Zoltán, P & László, S 2007, 'A humán leukocytainterferon helye a krónikus hepatitis C kezelésében', Lege Artis Medicinae, vol. 17, no. 11, pp. 783-786.
Telegdy L, Gábor H, Gyula T, Mihály M, Valéria M, Zsófia O et al. A humán leukocytainterferon helye a krónikus hepatitis C kezelésében. Lege Artis Medicinae. 2007 Nov;17(11):783-786.
Telegdy, L. ; Gábor, Horváth ; Gyula, Tolvaj ; Mihály, Makara ; Valéria, Montskó ; Zsófia, Ozsvár ; Zsuzsanna, Nemes ; Zoltán, Péterfy ; László, Szentgyörgyi. / A humán leukocytainterferon helye a krónikus hepatitis C kezelésében. In: Lege Artis Medicinae. 2007 ; Vol. 17, No. 11. pp. 783-786.
@article{912625e8c4cc478b9c1fc8d242b6dc4a,
title = "A hum{\'a}n leukocytainterferon helye a kr{\'o}nikus hepatitis C kezel{\'e}s{\'e}ben",
abstract = "INTRODUCTION - Approximatively 50{\%} of the patients with chronic hepatitis C do not respond properly to pegylated interferon-alpha+ribavirin treatment and according to the therapeutic guidelines their treatment must be interrupted. The authors examined whether their further medication with human leukocyte interferon is justified. PATIENTS AND METHODS - Thirty-eight patients with chronic hepatitis C were treated with human leukocyte interferon who had responded to pegylated interferon-alpha-ribavirin treatment, but dropped out of the treatment scheme based on the therapeutic criteria on week 12 or 24. RESULTS - While only 3 patients responded with persistent virological negativity, mean alanine aminotransferase (ALT) levels decreased during treatment and persistently remained lower than the baseline levels. Except for the three responders, the HCV viral load as determined by polymerase chain reaction did not decrease but even increased on average. Patients tolerated the treatment well. Known side-effects were observed in 6 cases, and treatment had to be interrupted in one case. These are proportionally far less than the respective 20 to 25{\%} and 5 to 15{\%} reported for peginterferon-ribavirin treatment. CONCLUSION - Even though virological recovery is rare, the reduction in inflammatory activity, the expected slowing of progression, and, in particular, the definite improvement of the cryoglobulinaemic purpura and vasculitis warrant switching to human leukocyte interferon treatment in selected cases.",
keywords = "Chronic hepatitis C, Human leukocyte interferon",
author = "L. Telegdy and Horv{\'a}th G{\'a}bor and Tolvaj Gyula and Makara Mih{\'a}ly and Montsk{\'o} Val{\'e}ria and Ozsv{\'a}r Zs{\'o}fia and Nemes Zsuzsanna and P{\'e}terfy Zolt{\'a}n and Szentgy{\"o}rgyi L{\'a}szl{\'o}",
year = "2007",
month = "11",
language = "Hungarian",
volume = "17",
pages = "783--786",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "11",

}

TY - JOUR

T1 - A humán leukocytainterferon helye a krónikus hepatitis C kezelésében

AU - Telegdy, L.

AU - Gábor, Horváth

AU - Gyula, Tolvaj

AU - Mihály, Makara

AU - Valéria, Montskó

AU - Zsófia, Ozsvár

AU - Zsuzsanna, Nemes

AU - Zoltán, Péterfy

AU - László, Szentgyörgyi

PY - 2007/11

Y1 - 2007/11

N2 - INTRODUCTION - Approximatively 50% of the patients with chronic hepatitis C do not respond properly to pegylated interferon-alpha+ribavirin treatment and according to the therapeutic guidelines their treatment must be interrupted. The authors examined whether their further medication with human leukocyte interferon is justified. PATIENTS AND METHODS - Thirty-eight patients with chronic hepatitis C were treated with human leukocyte interferon who had responded to pegylated interferon-alpha-ribavirin treatment, but dropped out of the treatment scheme based on the therapeutic criteria on week 12 or 24. RESULTS - While only 3 patients responded with persistent virological negativity, mean alanine aminotransferase (ALT) levels decreased during treatment and persistently remained lower than the baseline levels. Except for the three responders, the HCV viral load as determined by polymerase chain reaction did not decrease but even increased on average. Patients tolerated the treatment well. Known side-effects were observed in 6 cases, and treatment had to be interrupted in one case. These are proportionally far less than the respective 20 to 25% and 5 to 15% reported for peginterferon-ribavirin treatment. CONCLUSION - Even though virological recovery is rare, the reduction in inflammatory activity, the expected slowing of progression, and, in particular, the definite improvement of the cryoglobulinaemic purpura and vasculitis warrant switching to human leukocyte interferon treatment in selected cases.

AB - INTRODUCTION - Approximatively 50% of the patients with chronic hepatitis C do not respond properly to pegylated interferon-alpha+ribavirin treatment and according to the therapeutic guidelines their treatment must be interrupted. The authors examined whether their further medication with human leukocyte interferon is justified. PATIENTS AND METHODS - Thirty-eight patients with chronic hepatitis C were treated with human leukocyte interferon who had responded to pegylated interferon-alpha-ribavirin treatment, but dropped out of the treatment scheme based on the therapeutic criteria on week 12 or 24. RESULTS - While only 3 patients responded with persistent virological negativity, mean alanine aminotransferase (ALT) levels decreased during treatment and persistently remained lower than the baseline levels. Except for the three responders, the HCV viral load as determined by polymerase chain reaction did not decrease but even increased on average. Patients tolerated the treatment well. Known side-effects were observed in 6 cases, and treatment had to be interrupted in one case. These are proportionally far less than the respective 20 to 25% and 5 to 15% reported for peginterferon-ribavirin treatment. CONCLUSION - Even though virological recovery is rare, the reduction in inflammatory activity, the expected slowing of progression, and, in particular, the definite improvement of the cryoglobulinaemic purpura and vasculitis warrant switching to human leukocyte interferon treatment in selected cases.

KW - Chronic hepatitis C

KW - Human leukocyte interferon

UR - http://www.scopus.com/inward/record.url?scp=36348967032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348967032&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 783

EP - 786

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 11

ER -